ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Chrysanthemum Morifolium-Derived Nanovesicles Reduce Lactate-Associated Histone Lactylation and Modulate Microglia-Mediated Neuroinflammation in Sepsis-Associated Encephalopathy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Sepsis-associated encephalopathy (SAE)-a complication of the central nervous system in patients with sepsis-markedly diminishes cognitive functions and is linked to hippocampal neuritis-induced injury. Plant exosome-like nanovesicles can transport proteins, lipids, and molecular compounds between neural cells and the periphery, thereby modulating target cells. This study examined the therapeutic potential of Chrysanthemum morifolium-derived exosome-like nanovesicles (CRELNVs) in an animal model of lipopolysaccharide-induced SAE, revealing their ability to effectively cross the blood-brain barrier, be internalized by microglia, and alleviate nerve injury and memory impairment by reducing lactate levels in microglia at the hippocampus. CRELNVs decreased lactylation levels in microglia, thus promoting the conversion of microglial cells from the detrimental M1 metabolic phenotype to the protective M2 one. Mechanistically, our finding suggest CRELNVs reduced proinflammatory cytokine release is associated with the inhibition of NF-κB activation. Thus, CRELNVs were concluded to exert their protective effects by modulating the H3K18la/NF-κB axis and regulate microglia-mediated neuroinflammation by responding to the hippocampal neuritis-induced injury in SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.